Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sucampo Pharmaceuticals Inc.

Division of Mallinckrodt PLC
www.sucampo.com

Latest From Sucampo Pharmaceuticals Inc.

Zelnorm Returning To US Market With Broad IBS-C Indication

US FDA limiting use of Zelnorm, originally pulled from the market in 2007 by its then-sponsor Novartis, to adult women who are at low CV risk, but tegaserod is not restricted to patients who are severely symptomatic for IBS-C. 
Approvals Gastrointestinal

Asia Executives On The Move: BeiGene, Henlius, Dainippon Sumitomo

Another busy time for executive moves in the Asia Pacific region, as Amgen China GM joins Henlius, BeiGene appoints new immuno-oncology CMO and Sumitomo Dainippon names a new digital health head. Changes also take place at Ascentage, Harbin Pharma and AdvaMed.

Appointments Asia Pacific

Mallinckrodt Creating Two Companies: Generics And Innovative Specialty Drugs

The company, which makes generic opioid products and the controversial Acthar Gel, is looking to chart a new course for the future – or make that two new courses.

Business Strategies Companies

Zelnorm's Return: US FDA Panel Hands Down Split Decision On Constipation Drug's Target Population

Seven advisory committee members said the treatment for irritable bowel syndrome with constipation should be labeled for females at low cardiovascular risk; three panelists, including two cardiologists, supported a narrower indication limited to low CV risk patients who also suffer from severe symptoms.

Advisory Committees Drug Review
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Dermatology
  • Gastrointestinal
  • Metabolic Disorders
  • Neurology, Nervous System
  • Ophthalmic
  • Alias(es)
  • Sucampo AG
  • Sucampo Group
  • Sucampo Japan AG
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Mallinckrodt PLC
  • Senior Management
  • Peter Pfreundschuh, CFO
    Peter Kiener, CSO
    Woody Bryan, PhD, SVP, Bus. Dev. & Licensing
  • Contact Info
  • Sucampo Pharmaceuticals Inc.
    Phone: (301) 961-3400
    805 King Farm Blvd.
    Ste. 550
    Rockville, MD 20850
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register